Oculis Holding AG
OCS Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Oculis Holding AG had $1.4M of revenue in fiscal 2025, up 85.2% on the year before. Over five years, revenue changed +6.4% a year on average.
- Its operating margin was −6,811.8%, up 3,859.9 pts: of every 100 in sales, about −6,812 is left after running the business.
- Oculis Holding AG lost $119M in fiscal 2025.
- Free cash flow was −$80.1M in fiscal 2025, −5,555.1% of revenue.
Market cap
—
P/E
—
Revenue
$1.4M
Net income
−$119M
Free cash flow
−$80.1M
Operating margin
−6,811.8%
Oculis Holding AG in 30 seconds · fiscal 2025
Are sales growing?
+85.2%
Yes. Sales grew 85.2% last year.
Does it make a profit?
−8,253.4%
No. It lost money last year.
Does profit turn into cash?
−5,555.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
What Oculis Holding AG does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 4, 2026
- Legal name
- Oculis Holding AG
- CIK
- 0001953530
Oculis Holding AG · OCS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1M | $1.0M | $1.0M | $0.8M | $1.4M |
| Revenue growth | −0.7% | −9.1% | 2.9% | −20.7% | 85.2% |
| Net interest income | $0.0M | $0.1M | — | — | — |
| Operating margin | −1,378.3% | −3,549.9% | −9,140.9% | −10,671.6% | −6,811.8% |
| Net income | −$20.3M | −$40.5M | −$98.8M | −$97.4M | −$119M |
| Net margin | −1,932.5% | −4,243.0% | −10,056.8% | −12,504.5% | −8,253.4% |
| Diluted EPS | −$6.39 | −$11.85 | −$3.31 | −$2.41 | −$2.27 |
| Cash | |||||
| Cash from operations | −$15.1M | −$26.3M | −$61.3M | −$55.6M | −$79.8M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.3M | $0.4M |
| Free cash flow | −$15.2M | −$26.3M | −$61.3M | −$55.8M | −$80.1M |
| FCF margin | −1,443.0% | −2,756.4% | −6,238.4% | −7,164.9% | −5,555.1% |
| Share count change | 7.7% | 7.6% | 900.2% | 35.1% | 29.3% |
| Debt and strength | |||||
| Cash and short-term investments | $50.7M | $21.4M | $45.7M | $30.6M | $103M |
| Shareholders' equity | −$66.8M | −$106M | $112M | $81.0M | $247M |
| Current ratio | 11.8x | 2.0x | 5.3x | 2.4x | 6.0x |
| Interest coverage | −176.3x | −600.0x | −61.4x | −114.6x | −98.0x |
| Returns and quality | |||||
| Return on equity | — | — | −3,465.1% | −101.0% | −72.5% |
| Return on tangible equity | — | — | −101.6% | −146.9% | −51.6% |
| Piotroski F-score | — | 2 | 3 | 1 | 3 |
| Altman Z'' | −1.2 | −14.1 | −0.6 | −7.0 | 2.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Oculis Holding AG · OCS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001953530). Data updated October 24, 2026. Filed in CHF under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.